clinical trial · NCT06886360
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Dr. Falk Pharma GmbH·phase3·not yet recruiting·n = 120
Primary Sclerosing Cholangitisnorucholic acid
brief summary
Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
started
Mar 1, 2025
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Mar 20, 2025
official title
An Open-label Study of Patients with Primary Sclerosing Cholangitis (PSC) Treated with Norucholic Acid Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol